|Videos|September 27, 2021

Dr. Schweizer on olaparib plus bipolar androgen therapy in mCRPC

“The activity that we saw with the combination was very promising and…it justifies additional clinical trials to determine whether or not this could have a place in terms of our standard treatment options for patients,” says Michael Schweizer, MD.

In this video, Michael Schweizer, MD, discusses the background, findings, and takeaways of the study, “Bipolar androgen therapy (BAT) plus Olaparib in men with metastatic castration-resistant prostate cancer (mCRPC),” presented recently at the 2021 European Society for Medical Oncology Annual Meeting. Schweizer is an associate professor in the division of medical oncology at the University of Washington and an associate professor in the clinical research division at the Fred Hutchinson Cancer Research Center, Seattle, Washington

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME